Improving treatment outcomes in multidrug‐resistant tuberculosis (MDR‐TB) is partly
hampered by inadequate effective antitubercular agents. Development of bedaquiline and …

Background Linezolid was recently re‐classified as a Group A drug by the World Health
Organization (WHO) for treatment of multi‐drug resistant tuberculosis (MDR‐TB) and …

The treatment of multidrug-resistant (MDR) or extensively drug-resistant (XDR) tuberculosis
(TB) remains a challenge for clinicians for several reasons, including the large number of …

Relatively little is known about the efficacy and safety of the programmatic use of
bedaquiline and delamanid in multidrug-resistant tuberculosis (MDR-TB) treatment. This …

The lack of access to safe and effective antimicrobials for human populations is a threat to
global health security and a contributor to the emergence and spread of antimicrobial …

Optimal treatment regimens for patients with extensively drug-resistant tuberculosis (XDR-
TB) remain unclear. Long-term prospective outcome data comparing XDR-TB regimens with …

Multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) continue
to be challenging at both the patient and programme level. The World Health Organization …

Background Bedaquiline has a black-box warning of the risk of arrhythmias and sudden
death. This study aimed to determine the incidence of QTc prolongation and cardiac events …

The past decade has seen the emergence of new diagnostics and drugs for tuberculosis, a
disease that kills over 1.8 million people each year. However, these new tools are yet to …

Introduction: Outcomes of treatment for resistant tuberculosis are poor, with long treatment
duration and poor tolerability. Bedaquiline is a novel anti-mycobacterial drug, which has a …